drugset / Trial / NCT04359680

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

NCT04359680

Phase 3 Completed 1407 enrolled Romark Laboratories L.C.
RandomizedParallel-groupTriple-blindPrevention

Summary

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection

Timeline

Start
2020-05-13
Primary completion
2021-04-07
Completion
2021-04-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitazoxanide Other / unclassified 600 mg Oral